Bret Koplow has signed on with Sonnenschein Nath & Rosenthal as a partner in the firm’s Washington, D.C., office.
Koplow, who comes to Sonnenschein from Patton Boggs, will lead the firm’s Food and Drug Administration practice. He advises manufacturers of pharmaceutical products and medical devices before the FDA.
Koplow also represents drug manufacturers and health care providers before Congress and other regulatory bodies, including the Centers for Medicare and Medicaid Services, the National Institutes of Health, and other federal and state agencies.
“The demand for FDA counseling has never been greater, and Bret’s expertise immediately strengthens our work in this critical area for clients,” says Gadi Weinreich, national chair of Sonnenschein’s health care practice. “Bret’s profile and talents are exactly what we have been seeking.”
Koplow says he expects FDA regulation and health care reform to be a “principle focus” in Congress in the coming months.
“Congress is much more aggressive lately in overseeing and pushing the FDA for specific regulatory action. This is going to be a year or two years of intense focus on these issues,” Koplow says.